CY1110199T1 - Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων - Google Patents

Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων

Info

Publication number
CY1110199T1
CY1110199T1 CY20101100642T CY101100642T CY1110199T1 CY 1110199 T1 CY1110199 T1 CY 1110199T1 CY 20101100642 T CY20101100642 T CY 20101100642T CY 101100642 T CY101100642 T CY 101100642T CY 1110199 T1 CY1110199 T1 CY 1110199T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
neuroactive steroid
present
pregnan
methoxymethyl
Prior art date
Application number
CY20101100642T
Other languages
English (en)
Inventor
Richard M Woodward
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1110199T1 publication Critical patent/CY1110199T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

Η παρούσα εφεύρεση σχετίζεται με φαρμακευτικές συνθέσεις του νευροδραστικού στεροειδούς 3α-υδροξυ-3β-μεθοξυμεθυλο-21-(1'-ιμιδαζολυλο)-5α-πρεγναν-20-όνη ή ένα φαρμακευτικώς αποδεκτό άλας ή επιδιαλυτωμένη ένωση αυτής, με ιδιότητες επιθυμητές για χρήση στην αντιμετώπιση διαταραχών της διάθεσης και των παρόμοιων. Οι φαρμακευτικές συνθέσεις παρέχουν σταθερά θεραπευτικά επίπεδα 3α-υδροξυ-3β-μεθοξυμεθυλο-21-(1'-ιμιδαζολυλο)-5α-πρεγναν-20-όνης στο πλάσμα. Η παρούσα εφεύρεση επίσης σχετίζεται με μεθόδους αντιμετώπισης αυτών των διαταραχών με χορήγηση φαρμακευτικών συνθέσεων.
CY20101100642T 2005-06-09 2010-07-09 Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων CY1110199T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68890505P 2005-06-09 2005-06-09
EP06754274A EP1888080B1 (en) 2005-06-09 2006-06-09 Pharmaceutical compositions of a neuroactive steroid and uses thereof

Publications (1)

Publication Number Publication Date
CY1110199T1 true CY1110199T1 (el) 2015-01-14

Family

ID=36790861

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20101100642T CY1110199T1 (el) 2005-06-09 2010-07-09 Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
CY20121100298T CY1112499T1 (el) 2005-06-09 2012-03-21 Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20121100298T CY1112499T1 (el) 2005-06-09 2012-03-21 Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων

Country Status (26)

Country Link
US (2) US20090131383A1 (el)
EP (3) EP2168585B1 (el)
JP (2) JP2008542419A (el)
KR (3) KR20120028407A (el)
CN (1) CN101193640A (el)
AT (2) ATE538797T1 (el)
AU (1) AU2006256851C1 (el)
BR (1) BRPI0612921A2 (el)
CA (1) CA2611430C (el)
CY (2) CY1110199T1 (el)
DE (1) DE602006013622D1 (el)
DK (2) DK2168585T3 (el)
EA (1) EA013744B1 (el)
ES (2) ES2380060T3 (el)
HK (2) HK1118202A1 (el)
HR (2) HRP20100372T1 (el)
IL (3) IL187813A (el)
NO (1) NO20076319L (el)
NZ (1) NZ562979A (el)
PL (2) PL1888080T3 (el)
PT (2) PT2168585E (el)
RS (2) RS52199B (el)
SI (2) SI1888080T1 (el)
UA (1) UA94909C2 (el)
WO (1) WO2006131392A1 (el)
ZA (1) ZA200709188B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108976272B (zh) 2011-10-14 2021-05-25 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
PL2986623T3 (pl) 2013-04-17 2019-04-30 Sage Therapeutics Inc 19-nor C3,3-dipodstawione steroidy C21-n-pirazolilowe i sposoby ich stosowania
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
RU2019126333A (ru) 2013-04-17 2019-10-08 Сейдж Терапьютикс, Инк. 19-нор нейроактивные стероиды и способы их применения
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
PL3021852T3 (pl) 2013-07-19 2021-07-05 Sage Therapeutics, Inc. Neuroaktywne steroidy, kompozycje i ich zastosowania
RU2696585C2 (ru) 2013-08-23 2019-08-05 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применение
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3753927B1 (en) 2014-10-16 2023-07-19 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
MY190408A (en) * 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
EP3719029A1 (en) 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
EP3250210B1 (en) 2015-01-26 2020-12-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
RU2019103590A (ru) 2016-07-11 2021-02-11 Сейдж Терапьютикс, Инк. С17-, с20- и с21-замещенные нейроактивные стероиды и способы их применения
MX2020002652A (es) * 2017-09-07 2020-09-25 Sage Therapeutics Inc Esteroides neuroactivos y su método de uso.
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
CN113226326A (zh) * 2018-12-17 2021-08-06 细胞内治疗公司 有机化合物
CN113891715A (zh) * 2019-03-04 2022-01-04 普拉西斯精密医药公司 围绝经期和绝经期的治疗方法
PE20230244A1 (es) 2019-05-31 2023-02-07 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos
MX2022004022A (es) * 2019-10-02 2022-05-18 Praxis Prec Medicines Inc Combinaciones de moduladores alostericos positivos del receptor de gaba-a y antagonistas de nmda, moduladores alostericos negativos de nmda o agonistas parciales de nmda.
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
US20240148756A1 (en) 2021-02-18 2024-05-09 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
WO2022178000A1 (en) * 2021-02-18 2022-08-25 Praxis Precision Medicines, Inc. Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof
TW202308653A (zh) * 2021-04-26 2023-03-01 美商普雷西斯精密藥品股份有限公司 以神經活性類固醇進行治療的方法
WO2023159035A1 (en) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. Neuroactive steroids for treatment of cns-related disorders
WO2023159094A2 (en) * 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE
WO2023164386A1 (en) 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4884909A (en) 1986-12-25 1989-12-05 Canon Kabushiki Kaisha Recording apparatus
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
JP4066272B2 (ja) * 1994-02-14 2008-03-26 ユーロ‐セルティック エス． ア． Ｇａｂａ受容体のアロステリックな調節のためのアンドロスタン及びプレグナン類
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
UA73736C2 (en) * 1999-04-29 2005-09-15 Euro Celtic S A Method for alleviating or preventing insomnia and inducing anesthesia
US6387403B1 (en) * 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
US6080736A (en) * 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
US20060074059A1 (en) * 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one

Also Published As

Publication number Publication date
EP2168585A1 (en) 2010-03-31
AU2006256851B2 (en) 2009-12-17
AU2006256851A1 (en) 2006-12-14
EP1888080B1 (en) 2010-04-14
EP1888080A1 (en) 2008-02-20
JP2008542419A (ja) 2008-11-27
DK1888080T3 (da) 2010-07-19
HRP20120264T1 (hr) 2012-04-30
ZA200709188B (en) 2008-08-27
KR20120028407A (ko) 2012-03-22
KR20100095661A (ko) 2010-08-31
HK1140947A1 (en) 2010-10-29
WO2006131392A8 (en) 2007-02-15
EA013744B1 (ru) 2010-06-30
IL216194A0 (en) 2012-01-31
ES2344313T3 (es) 2010-08-24
JP2012229261A (ja) 2012-11-22
EP2168585B1 (en) 2011-12-28
IL187813A0 (en) 2008-08-07
UA94909C2 (ru) 2011-06-25
PL2168585T3 (pl) 2012-05-31
PL1888080T3 (pl) 2010-09-30
CA2611430C (en) 2013-09-10
NZ562979A (en) 2010-11-26
DK2168585T3 (da) 2012-02-27
PT2168585E (pt) 2012-03-05
WO2006131392A1 (en) 2006-12-14
SI2168585T1 (sl) 2012-04-30
IL187813A (en) 2011-12-29
ATE538797T1 (de) 2012-01-15
DE602006013622D1 (de) 2010-05-27
US20090131383A1 (en) 2009-05-21
US20120276196A1 (en) 2012-11-01
NO20076319L (no) 2007-12-07
HK1118202A1 (en) 2009-02-06
CY1112499T1 (el) 2015-12-09
EP2263675A2 (en) 2010-12-22
BRPI0612921A2 (pt) 2010-12-07
CN101193640A (zh) 2008-06-04
AU2006256851C1 (en) 2010-07-15
SI1888080T1 (sl) 2010-08-31
IL216194A (en) 2013-09-30
HRP20100372T1 (hr) 2010-08-31
KR20080017091A (ko) 2008-02-25
CA2611430A1 (en) 2006-12-14
EP2263675A3 (en) 2011-05-18
EA200800007A1 (ru) 2008-04-28
IL211114A (en) 2014-04-30
RS51304B (sr) 2010-12-31
ATE464054T1 (de) 2010-04-15
PT1888080E (pt) 2010-07-06
ES2380060T3 (es) 2012-05-08
RS52199B (en) 2012-10-31

Similar Documents

Publication Publication Date Title
CY1110199T1 (el) Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
CY1121134T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συγκολλησης
CY1119176T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες
CY1119865T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου του παρκινσον
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
CY1115477T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
CY1108324T1 (el) Νεοι τεταρτοταγοποιημενοι εστερες κουινουκλιδινης
CY1109196T1 (el) Συνδυασμος αζελαστινης και φλουτικαζονης
NO20074441L (no) 1-benzylindol-2-karboksamidderivater
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
CY1111541T1 (el) Αγωνιστες β-2 αδρενοϋποδοχεα για την αγωγη παθησεων συνδετικου ιστου του δερματος
SE0401342D0 (sv) Therapeutic compounds
CY1117504T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
CY1115384T1 (el) Αντι-φλεγμονωδης συνθεση
TW200732304A (en) Piperidine derivatives
TW200801005A (en) Acetylenic piperazines as metabotropic glutamate receptor antagonists
PL1732902T3 (pl) Pochodne nukleozydów i ich terapeutyczne zastosowanie
NZ588470A (en) Pharmaceutical composition comprising a benzophenone derivative and an immunosuppressing agent for treating autoimmune diseases
CY1117266T1 (el) 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντι-καρκινικοι παραγοντες
CY1114573T1 (el) Συνθεσεις και μεθοδοι για θεραπευτικη αγωγη ή αποτροπη γλαυκωματος ή πορειας αυτου
CY1114870T1 (el) Θειομολυβδαινικα αλατα και οι χρησεις τους
CY1114328T1 (el) Αμινοκινολονες ως gsk-3 αναστολεις